Internal restructuring
Bassin Parisien; Centre;
Location of affected unit(s)
Manufacturing Of Furniture And Other Manufacturing
Other Manufacturing
32.5 - Manufacture of medical and dental instruments and supplies

338 jobs
Number of planned job losses
Job loss
Announcement Date
16 October 2014
Employment effect (start)
7 March 2015
Foreseen end date
30 June 2015


Blood technology company Fenwal is to cut by 338 jobs. As reported, negotiations on the employment safeguard plan have started on 7 November and will last for four months. According to the sources the job reduction measure is linked with a drop of demand in blood transfusion in Europe, as public health authorities from several countries currently refused to pay blood transfusion for simple operations. Prices also have decreased about 25pc in the last three years.

The firm announced its intention to support job creation in the affected area and open positions in other plants within the group. There is no union within the plant, only a works council. On 25 October, 7,000 persons (twice the resident of the town of La Châtre) have demonstrated against the decision that is seen as a disaster for the local economy (the plant is the third biggest private employer in the department of Indre). The plant belongs since 2012 to the German medical equipment company Fresenius-Kabi. 


  • 22 October 2014: Les Echos
  • 16 October 2014: Le Télégramme
  • 7 November 2014: Le Monde


Eurofound (2014), Fenwal, Internal restructuring in France, factsheet number 77831, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/77831.